Compare PAGSEG Inc (PAGS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs Sanofi SA — how do they compare? PAGSEG Inc trades at $11.07 (market cap $2.94B), while Sanofi SA trades at $40.13 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 32.4× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (10.49%). Which is the better fit depends on your goals — on Pluang, investors hold PAGSEG Inc for 26 Days and Sanofi SA for 94 Days on average.
| PAGS | SNY | |
|---|---|---|
Market Cap | $2.94B | $95.18B |
Volume | 4,242,708 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $12.00 | $52.34 |
52-Week Low | $8.44 | $39.51 |
Typical Hold Time | 26 Days | 94 Days |
Enterprise Value | $11.02B | $114.48B |
Dividend Yield | 10.49% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $11.13, up 5.9% in the last 24 hours, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 7.1 and robust profitability, including a 10.45% net income margin. Recent earnings beat expectations in Q2 2026, and the company maintains a solid dividend yield, supported by positive cash flow from operations of $7.56B in 2025.
The outlook for PAGS is positive, driven by undervaluation and earnings growth potential, but risks include macroeconomic pressures in Brazil and increased credit losses. Analyst consensus is strongly bullish with a $10.70 price target, though near-term volatility may persist due to mixed technical oscillators and competitive challenges.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
